Evidence map›Paper›PMID 38849970›Full record

ArticlePhotochemistry and photobiology

Overcoming the effects of fluid shear stress in ovarian cancer cell lines: Doxorubicin alone or photodynamic priming to target platinum resistance.

Marta Overchuk, Brittany P Rickard, Justin Tulino, Xianming Tan, Frances S Ligler, Huang-Chiao Huang, Imran Rizvi

Abstract read
In one paragraph

Article in Photochemistry and photobiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marta OverchukJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, North Carolina, USA.ORCID 0000-0002-8203-0427
Brittany P RickardCurriculum in Toxicology & Environmental Medicine, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-6112-1290
Justin TulinoJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, North Carolina, USA.
Xianming TanDepartment of Biostatistics, University of North Carolina School of Public Health, Chapel Hill, North Carolina, USA.ORCID 0000-0002-5478-2269
Frances S LiglerDepartment of Biomedical Engineering, Texas A&M University, College Station, Texas, USA.ORCID 0000-0003-4909-2084
Huang-Chiao HuangFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.ORCID 0000-0002-5406-0733
Imran RizviJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, North Carolina, USA.ORCID 0000-0001-9673-4700

Funding

UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3M
TOXICOLOGYT32ES007126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ILONA JASPERS, Bernard E. Weissman · 1985 to 2026
$13.0M
Addressing Chemoresistance in Pancreatic and Ovarian Cancers: Photodynamic Priming and Repurposing of Tetracyclines using Targeted Photo-Activable Multi-Inhibitor LiposomeR01CA260340 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HUANG, HUANG CHIAO · 2021 to 2025
$3.2M
Targeting Fluid Stress-induced Chemoresistance in a 3D Carcinomatosis Perfusion Model Using Mechanism-based Photo-immunoconjugate NanoparticlesR01CA256710 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI Huang Chiao Huang, Imran Rizvi · 2023 to 2026
$2.2M
NCI NIH HHS R01 CA256710NCI NIH HHS R01 CA260340NIEHS NIH HHS P30 ES010126NIEHS NIH HHS T32 ES007126NIH HHS R01CA256710NIH HHS R01CA260340
6 · The paper itself

Abstract

Resistance to platinum-based chemotherapies remains a significant challenge in advanced-stage high-grade serous ovarian carcinoma, and patients with malignant ascites face the poorest outcomes. It is, therefore, important to understand the effects of ascites, including the associated fluid shear stress (FSS), on phenotypic changes and therapy response, specifically FSS-induced chemotherapy resistance and the underlying mechanisms in ovarian cancer. This study investigated the effects of FSS on response to cisplatin, a platinum-based chemotherapy, and doxorubicin, an anthracycline, both of which are commonly used to manage advanced-stage ovarian cancer. Consistent with prior research, OVCAR-3 and Caov-3 cells cultivated under FSS demonstrated significant resistance to cisplatin. Examination of the role of mitochondria revealed an increase in mitochondrial DNA copy number and intracellular ATP content in cultures grown under FSS, suggesting that changes in mitochondria number and metabolic activity may contribute to platinum resistance. Interestingly, no resistance to doxorubicin was observed under FSS, the first such observation of a lack of resistance under these conditions. Finally, this study demonstrated the potential of photodynamic priming using benzoporphyrin derivative, a clinically approved photosensitizer that localizes in part to mitochondria and endoplasmic reticula, to enhance the efficacy of cisplatin, but not doxorubicin, thereby overcoming FSS-induced platinum resistance.

Indexed as

CisplatinDoxorubicinDrug Resistance, NeoplasmOvarian NeoplasmsPhotochemotherapyAntineoplastic AgentsCell Line, TumorFemaleHumansMitochondriaPhotosensitizing AgentsStress, MechanicalAntineoplastic AgentsCisplatinDoxorubicinPhotosensitizing Agentsbenzoporphyrin derivativecisplatindoxorubicinhigh‐grade serous ovarian carcinomaovarian cancerphotodynamic priming

Identifiers

PMID38849970
PMCPMC11568959

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.